The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2017 | Can chemoimmunotherapy in CLL treatment be replaced with novel agents?
Barbara Eichhorst, MD, from University Hospital Cologne, Cologne, Germany, provides us an insight into the outcomes of a Phase II trial evaluating the efficacy and safety of a combined regimen of obinutuzumab and venetoclax in patients with chronic lymphocytic leukemia (CLL) (NCT02242942). She also outlines the background and outcomes of a Phase III trial evaluating if standard chemoimmunotherapy (FCR, BR) in frontline treatment of CLL patients can be replaced by combinations of targeted drugs (venetoclax, ibrutinib) with anti-CD20-antibodies (rituximab, obinutuzumab) (NCT02950051) and notes that the future of CLL treatment is likely to be chemoimmunotherapy-free. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
